TC-1827 is an orally active, selective agonist of the α4β2 nicotinic receptors. Administration of TC-1827 improved memory and learning in a variety of rodents and increased long-term potentiation in hippocampal slices. In addition, the compound was without significant cardiovascular side effects, except for a small, transient rise in arterial blood pressure. The pro-cognitive effects of TC-1827 last much longer than the short half life (0.2 - 1.0 hours) would suggest.[1]

TC-1827
Names
Preferred IUPAC name
(2S,4E)-N-Methyl-5-(pyrimidin-5-yl)pent-4-en-2-amine
Identifiers
3D model (JSmol)
ChemSpider
  • InChI=1S/C10H15N3/c1-9(11-2)4-3-5-10-6-12-8-13-7-10/h3,5-9,11H,4H2,1-2H3/b5-3+/t9-/m0/s1
    Key: VZNTWLIIJWUCEP-SGRBOOSSSA-N
  • C[C@H](NC)C/C=C/C1=CN=CN=C1
Properties
C10H15N3
Molar mass 177.251 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

References

edit
  1. ^ Bohme, Georg Andrees (May 2004). "In vitro and in vivo characterization of TC-1827, a novel brain α4β2 nicotinic receptor agonist with pro-cognitive activity". Drug Development Research. 62 (1): 26–40. doi:10.1002/ddr.10352. S2CID 86072368.